Component of a Polycomb group (PcG) multiprotein PRC1- like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. In the PRC1 complex, it is required to stimulate the E3 ubiquitin-protein ligase activity of RNF2/RING2. Component of a PRC1-like complex. Interacts with RING1 and RING2. Interacts vwith CBX7 and CBX8. Interacts with SPOP. Part of a complex consisting of BMI1, CUL3 and SPOP. Interacts with E4F1. Note: This description may include information from UniProtKB.
Molecular Function: protein binding; zinc ion binding; sequence-specific DNA binding; ubiquitin-protein ligase activity; chromatin binding
Biological Process: transcription, DNA-dependent; in utero embryonic development; positive regulation of immature T cell proliferation in the thymus; negative regulation of transcription from RNA polymerase II promoter; humoral immune response; embryonic skeletal morphogenesis; segment specification; rostrocaudal neural tube patterning; positive regulation of fibroblast proliferation; regulation of gene expression; positive regulation of ubiquitin-protein ligase activity; histone ubiquitination; positive regulation of B cell proliferation; DNA methylation; somatic stem cell division; hemopoiesis; histone acetylation; brain development
Alt. Names/Synonyms: B lymphoma Mo-MLV insertion region 1 homolog; BMI1; BMI1 polycomb ring finger oncogene; flvi-2/bmi-1; MGC12685; murine leukemia viral (bmi-1) oncogene homolog; oncogene BMI-1; PCGF4; Polycomb complex protein BMI-1; polycomb group protein Bmi1; polycomb group ring finger 4; Polycomb group RING finger protein 4; RING finger protein 51; RNF51
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.